Daratumumab-Based Second Line Therapy Improves Outcomes After VRD Induction, Upfront Autologous Transplant, and Lenalidomide Maintenance
Clinical Lymphoma Myeloma and Leukemia · 2026-05 · 26 (5) · e683-e689.e5
DOI: 10.1016/j.clml.2026.02.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-05. Verfasst von Oren Pasvolsky und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Lenalidomide, Multiple Myeloma, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health National Cancer Institute, University of Texas MD Anderson Cancer Center.
Abstract (Originalsprache)
Background
For eligible patients with newly diagnosed multiple myeloma (MM), induction with bortezomib, lenalidomide, and dexamethasone (VRD) used to be the standard of care until a few years ago, when it was gradually replaced by Daratumumab + VRD (Dara-VRD), followed by autologous stem cell transplantation (autoHCT) and lenalidomide maintenance. Most patients relapse and require second-line (2L) therapy. Patients and Methods: We conducted a retrospective, single-center study of MM patients who received VRD induction, upfront autoHCT between 2005 and 2021, and lenalidomide maintenance before relapse.
Results
146 patients were included, with a median age of 60 years (range 32–80), and 39 (27%) patients had high-risk cytogenetics. Following first progression, 31% (n=45) received an immunomodulatory drug (IMiD) + proteasome inhibitor (PI)-containing triplet as 2L therapy, 21% (n=30) received an IMiD/PI-containing doublet, and 24% (n=35) received a daratumumab (Dara)-based 2L therapy. Patients receiving Dara-based regimens had higher rates of ≥VGPR (63%) compared to those receiving other regimens (IMiD+PI triplet: 35%, IMiD/PI doublet: 34%) (p=0.026). After a median follow-up of 35.8 months from 2L therapy, median PFS2 with Dara-based regimens was 59.9 months, versus 12.3 months and 11.5 months for doublets and triplets, respectively (p=0.007). Median OS from initiation of second-line therapy for the entire cohort was 52.6 months. In multivariable analysis, Dara-based therapy was associated with improved PFS2 (HR 0.35, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Division of Hematology, Dalhousie University, Halifax, Nova Scotia, Canada.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hematology/Oncology, McGovern Medical School, The University of Texas, Health S…
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Förderung
- NCI NIH HHS
- National Institutes of Health National Cancer Institute
- University of Texas MD Anderson Cancer Center
- Paula and Rodger Riney Foundation
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Zitieren
APA
Pasvolsky, O., Marcoux, C., Milton, D. R., Tanner, M. R., Bashir, Q., Srour, S., Saini, N., Lin, P., Siddiqui, U. R., Khan, H. N., Haider, A. A., Ramdial, J., Nieto, Y., Tang, G., Lakhani, K., Aljawai, Y., Kebriaei, P., Lee, H. C., Patel, K. K., …, & Qazilbash, M. H. (2026). Daratumumab-Based Second Line Therapy Improves Outcomes After VRD Induction, Upfront Autologous Transplant, and Lenalidomide Maintenance. Clinical Lymphoma Myeloma and Leukemia, 26(5), e683-e689.e5. https://doi.org/10.1016/j.clml.2026.02.014
Vancouver
Pasvolsky O, Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, et al. Daratumumab-Based Second Line Therapy Improves Outcomes After VRD Induction, Upfront Autologous Transplant, and Lenalidomide Maintenance. Clinical Lymphoma Myeloma and Leukemia. 2026;26(5):e683-e689.e5. doi:10.1016/j.clml.2026.02.014
BibTeX
@article{Pasvolsky2026,
author = {Pasvolsky, Oren and Marcoux, Curtis and Milton, Denái R and Tanner, Mark R and Bashir, Qaiser and Srour, Samer and Saini, Neeraj and Lin, Paul and Siddiqui, Umer R and Khan, Hina N and Haider, Asad A and Ramdial, Jeremy and Nieto, Yago and Tang, Guilin and Lakhani, Kiran and Aljawai, Yosra and Kebriaei, Partow and Lee, Hans C and Patel, Krina K and Thomas, Sheeba K and Orlowski, Robert Z and Champlin, Richard E and Shpall, Elizabeth J and Qazilbash, Muzaffar H},
title = {Daratumumab-Based Second Line Therapy Improves Outcomes After VRD Induction, Upfront Autologous Transplant, and Lenalidomide Maintenance},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
volume = {26},
number = {5},
pages = {e683--e689.e5},
doi = {10.1016/j.clml.2026.02.014}
}
EUVIMED